Cargando…

Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS

BACKGROUND: The homogentisic acid‐lowering therapy nitisinone is being evaluated for the treatment of alkaptonuria (AKU) at the National Centre for AKU. Beyond hypertyrosinemia, the wider metabolic consequences of its use are largely unknown. The aim of this work was to evaluate the impact of nitisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davison, Andrew S., Norman, Brendan P., Ross, Gordon A., Hughes, Andrew T., Khedr, Milad, Milan, Anna M., Gallagher, James A., Ranganath, Lakshminarayan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606987/
https://www.ncbi.nlm.nih.gov/pubmed/31392115
http://dx.doi.org/10.1002/jmd2.12042
_version_ 1783432007580123136
author Davison, Andrew S.
Norman, Brendan P.
Ross, Gordon A.
Hughes, Andrew T.
Khedr, Milad
Milan, Anna M.
Gallagher, James A.
Ranganath, Lakshminarayan R.
author_facet Davison, Andrew S.
Norman, Brendan P.
Ross, Gordon A.
Hughes, Andrew T.
Khedr, Milad
Milan, Anna M.
Gallagher, James A.
Ranganath, Lakshminarayan R.
author_sort Davison, Andrew S.
collection PubMed
description BACKGROUND: The homogentisic acid‐lowering therapy nitisinone is being evaluated for the treatment of alkaptonuria (AKU) at the National Centre for AKU. Beyond hypertyrosinemia, the wider metabolic consequences of its use are largely unknown. The aim of this work was to evaluate the impact of nitisinone on the serum metabolome of patients with AKU after 12 and 24 months of treatment. METHODS: Deproteinized serum from 25 patients with AKU (mean age[±SD] 51.1 ± 14.9 years, 12 male) was analyzed using the 1290 Infinity II liquid chromatography system coupled to a 6550 quadrupole time‐of‐flight mass spectrometry (Agilent, UK). Raw data were processed using a batch targeted feature extraction algorithm and an accurate mass retention time database containing 469 intermediary metabolites (MW 72‐785). Matched entities (±10 ppm theoretical accurate mass and ±0.3 minutes retention time window) were filtered based on their frequency and variability (<25% CV) in group quality control samples, and repeated measures statistical significance analysis with Benjamini‐Hochberg false discovery rate adjustment was used to assess changes in metabolite abundance. RESULTS: Eight metabolites increased in abundance (log(2) fold change [FC] 2.1‐15.2, P < .05); 7 of 8 entities were related to tyrosine metabolism, and 13 decreased in abundance (log(2) FC 1.5‐15.5, P < .05); including entities related to tyrosine (n = 2), tryptophan (n = 3), xanthine (n = 2), and citric acid cycle metabolism (n = 2). CONCLUSIONS: Evaluation of the serum metabolome of patients with AKU showed a significant difference in the abundance of several metabolites following treatment with nitisinone, including a number that have not been previously reported; several of these were not related to the tyrosine metabolic pathway. SYNOPSIS: Nitisinone therapy has a significant impact on several metabolites beyond the tyrosine metabolic pathway, several of which appear to be related to the redox state of the cell.
format Online
Article
Text
id pubmed-6606987
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-66069872019-08-07 Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS Davison, Andrew S. Norman, Brendan P. Ross, Gordon A. Hughes, Andrew T. Khedr, Milad Milan, Anna M. Gallagher, James A. Ranganath, Lakshminarayan R. JIMD Rep Research Reports BACKGROUND: The homogentisic acid‐lowering therapy nitisinone is being evaluated for the treatment of alkaptonuria (AKU) at the National Centre for AKU. Beyond hypertyrosinemia, the wider metabolic consequences of its use are largely unknown. The aim of this work was to evaluate the impact of nitisinone on the serum metabolome of patients with AKU after 12 and 24 months of treatment. METHODS: Deproteinized serum from 25 patients with AKU (mean age[±SD] 51.1 ± 14.9 years, 12 male) was analyzed using the 1290 Infinity II liquid chromatography system coupled to a 6550 quadrupole time‐of‐flight mass spectrometry (Agilent, UK). Raw data were processed using a batch targeted feature extraction algorithm and an accurate mass retention time database containing 469 intermediary metabolites (MW 72‐785). Matched entities (±10 ppm theoretical accurate mass and ±0.3 minutes retention time window) were filtered based on their frequency and variability (<25% CV) in group quality control samples, and repeated measures statistical significance analysis with Benjamini‐Hochberg false discovery rate adjustment was used to assess changes in metabolite abundance. RESULTS: Eight metabolites increased in abundance (log(2) fold change [FC] 2.1‐15.2, P < .05); 7 of 8 entities were related to tyrosine metabolism, and 13 decreased in abundance (log(2) FC 1.5‐15.5, P < .05); including entities related to tyrosine (n = 2), tryptophan (n = 3), xanthine (n = 2), and citric acid cycle metabolism (n = 2). CONCLUSIONS: Evaluation of the serum metabolome of patients with AKU showed a significant difference in the abundance of several metabolites following treatment with nitisinone, including a number that have not been previously reported; several of these were not related to the tyrosine metabolic pathway. SYNOPSIS: Nitisinone therapy has a significant impact on several metabolites beyond the tyrosine metabolic pathway, several of which appear to be related to the redox state of the cell. John Wiley & Sons, Inc. 2019-05-31 /pmc/articles/PMC6606987/ /pubmed/31392115 http://dx.doi.org/10.1002/jmd2.12042 Text en © 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
Davison, Andrew S.
Norman, Brendan P.
Ross, Gordon A.
Hughes, Andrew T.
Khedr, Milad
Milan, Anna M.
Gallagher, James A.
Ranganath, Lakshminarayan R.
Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
title Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
title_full Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
title_fullStr Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
title_full_unstemmed Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
title_short Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
title_sort evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using lc‐qtof‐ms
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606987/
https://www.ncbi.nlm.nih.gov/pubmed/31392115
http://dx.doi.org/10.1002/jmd2.12042
work_keys_str_mv AT davisonandrews evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT normanbrendanp evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT rossgordona evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT hughesandrewt evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT khedrmilad evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT milanannam evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT gallagherjamesa evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms
AT ranganathlakshminarayanr evaluationoftheserummetabolomeofpatientswithalkaptonuriabeforeandaftertwoyearsoftreatmentwithnitisinoneusinglcqtofms